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Abstract: The kynurenine pathway (KP) is a major route of L-tryptophan catabolism resulting in the production of the 
essential pyridine nucleotide nicotinamide adenine dinucleotide, (NAD
+). Up-regulation of the KP during inﬂ  ammation 
leads to the release of a number of biologically active metabolites into the brain. We hypothesised that while some of the 
extracellular KP metabolites may be beneﬁ  cial for intracellular NAD
+ synthesis and cell survival at physiological concentra-
tions, they may contribute to neuronal and astroglial dysfunction and cell death at pathophysiological concentrations. In 
this study, we found that treatment of human primary neurons and astrocytes with 3-hydroxyanthranilic acid (3-HAA), 
3-hydroxykynurenine (3-HK), quinolinic acid (QUIN), and picolinic acid (PIC) at concentrations below 100 nM signiﬁ  cantly 
increased intracellular NAD
+ levels compared to non-treated cells. However, a dose dependent decrease in intracellular 
NAD
+ levels and increased extracellular LDH activity was observed in human astrocytes and neurons treated with 3-HAA, 
3-HK, QUIN and PIC at concentrations 100 nM and kynurenine (KYN), at concentrations above 1 μM. Intracellular 
NAD
+ levels were unchanged in the presence of the neuroprotectant, kynurenic acid (KYNA), and a dose dependent increase 
in intracellular NAD
+ levels was observed for TRP up to 1 mM. While anthranilic acid (AA) increased intracellular NAD
+ 
levels at concentration below 10 μM in astrocytes. NAD
+ depletion and cell death was observed in AA treated neurons at 
concentrations above 500 nM. Therefore, the differing responses of astrocytes and neurons to an increase in KP metabolites 
should be considered when assessing KP toxicity during neuroinﬂ  ammation.
Introduction
Tryptophan (TRP) catabolism via the kynurenine pathway (KP) represents the major pathway for the 
synthesis of nicotinamide adenine dinucleotide (NAD
+).
1 Essential NAD
+ dependent reactions can be 
divided into three main categories:
2 (1) NAD
+ is an important contributor to energy (ATP) production;
3 
(2) NAD
+ serves as a cofactor for NAD glycohydrolases involved in intracellular calcium regulation;
4,5 
(3) NAD
+ is a substrate for the family of DNA nick sensing poly(ADP-ribose) polymerases (PARP)
6–8 
and the class III histone deacetylases known as sirtuins.
9,10 NAD
+ levels are extremely volatile and can 
be signiﬁ  cantly reduced under conditions of excessive PARP-1 activation caused by oxidative damage 
to DNA, and during mitosis.
11 Thus, continuous biosynthesis of NAD
+ is vital to the maintenance and 
ongoing cell viability of all cells.
12
The KP is the principal route of L-tryptophan catabolism, resulting in the production of NAD
+ (Fig. 1). 
Over-activation of the KP has been implicated in the pathogenesis of several neurological disorders 
including Huntington’s disease (HD), Alzheimer’s disease (AD), and the acquired immunodeﬁ  ciency 
syndrome (AIDS)-dementia complex.
13–17 The pathway is regulated by the immune-factor responsive 
enzyme indoleamine-2,3-dioxygenase (IDO) in most cells and by tryptophan-2,3 dioxygenase (TDO) 
in the liver which is modulated by tryptophan and glucocorticoids.
18,19
Several intermediate products of the KP are known to be neurotoxic. Among them, the N-methyl-
D-aspartate (NMDA) receptor agonist and neurotoxin, quinolinic acid (QUIN) is likely to be most important 
in terms of biological activity.
15 Anthranilic acid (AA), 3-hydroxyanthranilic acid (3-HAA), and 
3-hydroxykynurenine (3-HK) have been shown to generate free radicals leading to neuronal damage 
similar to QUIN.
15 The early upstream KP metabolite kynurenic acid (KYNA), has been shown to antagonise the 62
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neurotoxic effects of QUIN and glutamate-mediated 
NMDA receptor activation.
20,21 The downstream 
metabolite picolinic acid (PIC) is an endogenous 
metal chelator within the brain
22,23 that displays some 
protection against QUIN induced toxicity and 
posesses immune regulatory activity.
24,25
Given the signiﬁ  cance of intracellular NAD
+ 
levels for the maintenance of total cell integrity 
and cell viability, we used primary monocultures 
of human neurons and astrocytes treated with 
physiological and pathophysiological concentra-
tions of TRP, KYN, KYNA, AA, 3-HAA, 3-HK, 
PIC, and QUIN respectively (0.1–100 μM). Intra-
cellular NAD
+ levels were measured using the 
thiazolyl blue microcycling assay. The effect of 
KP metabolites on cell viability was determined 
by measuring the release of lactate dehydrogenase 
into the extracellular medium.
NAD
+
3-Hydroxyanthranilic 
Acid
2-Amino-3-
Carboxymuconic 
Semialdehyde
Quinolinic Acid
E
F
H
J
K
D
A
C
L-Tryptophan
L-Formylkynurenine
L-Kynurenine
3-Hydroxykynurenine
Kynurenic Acid
I
Glutaryl-
CoA
Acetyl-
CoA
Picolinic Acid
B
Anthranilic Acid
F
G
Missing in
Astrocytes
H
COOH
COOH
COOH
COOH
COOH
COOH
COOH
COOH
C
C
C
COOH
HOOC
CHC
OH
OH
HO
O
O
O
NH2
NH2
NH2
NH2
NH2
NH2
NH2
H3N
HN CHO
N
COOH
N
H
Figure 1. The Kynurenine Pathway of Tryptophan Degradation. A) Indoleamine 2,3-dioxygenase (IDO); B) Tryptophan 2,3 dioxygenase 
(TDO) C) Kynurenine Formylase; D) Kynurenine-Amino Transferase; E) Kynurenine 3Hydroxylase; F) Kynureninase; G) Non-speciﬁ  c 
hydroxylation; H) 3-Hydroxyanthranilic Acid Oxidase; I) Picolinic Carboxylase J) Non-enzymatic cyclisation; K) Quinolinic Acid Phosphori-
bosyltransferase.63
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Materials and Methods
Reagents and chemicals
Dulbecco’s phosphate buffer solution (DBPS) and 
all other cell culture media and supplements were 
from Invitrogen (Melbourne, Australia) unless oth-
erwise stated. Nicotinamide, bicine, β-nicotinamide 
adenine dinucleotide reduced form (β-NADH), 
3-[-4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazo-
lium bromide (MTT), alcohol dehydrogenase 
(ADH), sodium pyruvate, TRIS, γ-globulins, 
L-tryptophan (TRP), kynurenine (KYN), kynurenic 
acid (KYNA), anthranilic acid (AA), 3-hydroxyan-
thranilic acid (3-HAA), 3-hydroxykynurenine 
(3-HK), picolinic acid (PIC), and quinolinic acid 
(QUIN) were obtained from Sigma-Aldrich 
(Castle-Hill, Australia). Phenazine methosulfate 
(PMS) was obtained from ICN Biochemicals (Ohio, 
U.S.A). Bradford reagent was obtained from BioRad, 
Hercules (CA, U.S.A).
Cell cultures
Human foetal brains were obtained from 16–19 week 
old foetuses collected following therapeutic termina-
tion with informed consent. Mixed brain cultures 
were prepared and maintained using a protocol pre-
viously described by Guillemin et al.
26 Astrocytes 
and neurons were prepared from the mixed brain cell 
cultures, and maintained using a protocol previously 
described by Guillemin et al.
27
Primary brain cells and KP metabolite 
culture treatments
Human primary astrocytes and neurons were 
incubated with various concentrations of the KP 
metabolites (0.1–100 μM) for 24 hours. Experiments 
were performed with primary cultures derived from 
three different human foetal brains with each indi-
vidual preparation tested in triplicate.
NAD(H) Microcycling assay 
for the measurement of intracellular 
NAD
+ concentrations
Intracellular NAD
+ concentration following 24 hour 
incubation with the desired concentrations of KP 
metabolites were measured spectrophotometrically 
using the thiazolyl blue microcycling assay estab-
lished by Bernofsky and Swan
28 adapted for 96 well 
plate format by Grant and Kapoor.
29
Extracellular LDH activity 
as a measurement for cytotoxicity
The release of lactate dehydrogenase (LDH) into 
culture supernatant correlates with the amount of 
cell death and membrane damage, providing an 
accurate measure of cellular toxicity. LDH activity 
following 24 hour incubation with the desired 
concentrations of KP metabolites was assayed 
using a standard spectrophotometric technique 
described by Koh and Choi.
30
Bradford protein assay 
for the quantiﬁ  cation of total protein
NAD
+ concentration and extracellular LDH activity 
were adjusted for variations in cell number using the 
Bradford protein assay described by Bradford.
31
Data analysis
Results obtained are presented as the means ± the 
standard error of measurement (SEM). Signiﬁ  cant 
differences between results were veriﬁ  ed using the 
two-tailed t-test with equal variance. Differences 
between treatment groups were considered signiﬁ  -
cant if p was less than 0.05 (p  0.05).
Results
Effect of extracellular KP metabolites 
on intracellular NAD
+ concentrations 
in human astrocytes and neurons
TRP induced a dose-dependent increase in intracel-
lular NAD
+ levels in both human neurons 
(at 100 nM TRP) and astrocytes (at 500 nM 
TRP), (Fig. 2). We found that 3-HAA, 3-HK, QUIN 
and PIC signiﬁ  cantly increased intracellular NAD
+ 
levels at a low concentration of 100 nM but sub-
stantially decreased NAD
+ levels at higher con-
centrations (Fig. 2) in both cell types. Treatment 
with KYNA had no signiﬁ  cant effect on intracel-
lular NAD
+ activity in either neuronal or astroglial 
cultures (Fig. 2). A dose-dependent decrease in 
intracellular NAD
+ levels was observed in KYN 
treated astrocytes and neurons at concentra-
tions above 1 μM. AA increased intracellular 
NAD
+ levels at concentrations below 50 μM in 
human astrocytes. However in human neurons 
NAD
+ depletion was observed at AA concentra-
tions 500 nM for neurons and 100 μM for 
astrocytes (Fig. 2).64
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Figure 2. The effect of KP metabolites on intracellular NAD
+ levels in human neurons and astrocytes. (Control = 0 μM treatment for each 
metabolite and cell type) A) The effect of TRP (1–1000 μM) on intracellular NAD
+ in human neurons and astrocytes after 24 hours. *p  0.05 
compared to control in human neurons. ¥p  0.05 compared to control in human astrocytes. B) The effect of KYN (1–1000 μM) on intracellular 
NAD
+ in human neurons and astrocytes after 24 hours. *p  0.05 compared to control in human neurons. ¥p  0.05 compared to control in 
human astrocytes. C) The effect of KYNA (1–1000 μM) on intracellular NAD
+ in human neurons and astrocytes after 24 hours. *p  0.05 
compared to control in human neurons. ¥p  0.05 compared to control in human astrocytes. D) The effect of 3-HAA (1–1000 μM) on 
intracellular NAD
+ in human neurons and astrocytes after 24 hours. *p  0.05 compared to control in human neurons. ¥p  0.05 compared 
to control in human astrocytes. E) The effect of 3HK (1–1000 μM) on intracellular NAD
+ in human neurons and astrocytes after 24 hours. 
*p  0.05 compared to control in human neurons. ¥p  0.05 compared to control in human astrocytes. F) The effect of AA (1–1000 μM) on 
intracellular NAD
+ in human neurons and astrocytes after 24 hours. *p  0.05 compared to control in human neurons. ¥p  0.05 compared 
to control in human astrocytes. G) The effect of QUIN (1–1000 μM) on intracellular NAD
+ in human neurons and astrocytes after 24 hours. 
*p  0.05 compared control in human neurons. ¥p  0.05 compared to control in human astrocytes. H) The effect of PIC (1–1000 μM) on 
intracellular NAD
+ in human neurons and astrocytes after 24 hours. *p  0.05 compared to control in human neurons. ¥p  0.05 compared 
to control in human astrocytes. (n = 3 for each treatment group).65
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Effect of extracellular KP metabolites 
on extracellular LDH activity in human 
astrocytes and neurons
Consistent with the results obtained for intracellular 
NAD
+ levels, no signiﬁ  cant change was observed 
in extracellular LDH activity for both astrocyte and 
neuronal cultures treated with TRP or KYNA up to 
1 mM (Fig. 3). However treatment with 3-HAA, 
3-HK, QUIN and PIC increased extracellular LDH 
activity at concentrations above 100 nM (Fig. 3) in 
both cell types. A dose-dependent increase in extra-
cellular LDH activity was observed in astrocytes 
and neurons treated with KYN at concentrations 
above 1 μM. However the magnitude of LDH 
release following KYN treatment was signiﬁ  cantly 
less than that observed for any of the other toxic 
metabolites. LDH activity was also increased for 
cells treated with AA at concentrations above 
100 nM in astrocytes and at or above 100 nM in 
neurons (Fig. 3).
Discussion
Neurodegenerative diseases are often characterised 
by a loss of neuronal cells in speciﬁ  c regions of the 
brain. Given the importance of intracellular NAD
+ 
levels for maintaining overall cellular integrity and 
function, it is conceivable that reduced NAD
+ levels 
are a potential pathogenic mechanism for neuronal 
and astroglial cell death.
11,8 TRP has been used as a 
supplement for some years in the United States 
before being removed due to an outbreak of the lethal 
autoimmune disease, eosinophilia-myalgia syn-
drome (EMS) resulting in 36 deaths.
11 Large doses 
of TRP can induce the build-up of selected white 
blood cells leading to EMS. Since the KP is a major 
regulator of the immune response,
32 the toxic effect 
may be due to inhibition of normal tolerogenic cell 
T-cell death following IDO induction.
11
In this study, we found that TRP supplementa-
tion produced a dose-dependent increase in intra-
cellular NAD
+ levels in human astrocytes and 
neurons after 24 hours (Fig. 2). The physiological 
concentration of TRP is human plasma is estimated 
to be 40–90 μM.
33,34 Lower serum concentrations 
have been observed in several disorders including 
depression and anxiety,
35 rheumatoid arthritis
36 and 
following infection with HIV.
33 TRP supplementa-
tion has been previously shown to be beneﬁ  cial in 
several neurological conditions, including insom-
nia and depression, since TRP can be used for the 
synthesis of serotonin, melatonin and NAD
+.
11,19 
Moreover, under conditions of TRP depletion, 
supplementation with TRP down-regulates 
enzymes directing TRP to non-NAD
+ dependent 
pathways,
19 suggesting a shift of all available TRP 
catabolism to NAD
+ synthesis.
37 However, it is 
clear that excessive TRP supplementation would 
aggravate or induce autoimmune disease.
11
The primary metabolite of TRP, N-formylkyn-
urenine can be rapidly converted to KYN by the 
enzyme arylamine formamidase.
38 KYN (its 
physiological concentration is 1 μM) is converted 
into several neurotoxic metabolites such as 3-HK 
and QUIN in unstimulated human brain cells.
39,14 
Our data indicates that KYN causes intracellular 
NAD
+ depletion and reduced cell viability at greater 
than physiological concentrations (Figs. 2 and 3). 
Human astrocytes and microglial cells demonstrate 
rapid cellular uptake of KYN. KYN has been shown 
to increase QUIN production and KP enzyme 
expression in human macrophages.
27 The enhanced 
generation of QUIN may account for the reduced 
NAD
+ levels and increased cytotoxicity observed 
in human neurons and astrocytes at pathophysio-
logical concentrations (Figs. 2 and 3).
KYN and the resulting metabolite, 3-HK can be 
converted to AA and 3-HAA by kynureninase.
15 
These metabolites also provide additional substrate 
for QUIN formation.
40 The levels of 3-HK, AA and 
3-HAA are signiﬁ  cantly increased in the CSF of 
patients with HD.
41 Elevated levels have also been 
reported in HIV cases associated with dementia, 
infantile spasms, and hepatic encephalopathy.
40 
While 3-HK, AA, and 3-HAA appear less neurotoxic 
than QUIN, these KP metabolites have been 
previously shown to promote neuronal damage 
largely through free radical formation but not NMDA 
receptor activation.
15 Under normal conditions, the 
serum concentration of 3-HK, 3-HAA and AA has 
been found to be 383 nM,
42 24 nM
35 and 21 nM,
34 
respectively. In this study, we found that 3-HK, AA 
and 3-HAA supplementation resulted in neuronal 
and astroglial NAD
+ depletion and cell death in 24 
hour cultures at micromolar concentrations (Fig. 1 
and Fig. 2). These results are consistent with a previ-
ous study showing that 3-HK, 3-HAA, and AA also 
induced a time-and dose-dependent increase in cell 
death at micromolar concentrations (1–100 μM).
41 
These authors reported that the accompanying cell 
death was signiﬁ  cantly reduced by co-treatment with 
catalase, suggesting that the neurotoxic effects of 
3-HK may be mediated by increased hydrogen per-
oxide.
41 3-HK can be converted to quinoneimines 66
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LDH activity in human neurons and astrocytes after 24 hours. *p  0.05 compared to control in human neurons. ¥p  0.05 compared to control 
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that can generate pro-oxidant intermediates, such as 
hydrogen peroxide, organic and hydroxyl radicals, 
during processes of autoxidation.
43,44 Similarly, 3-
HK has been shown to potentiate QUIN toxicity in 
rats, and the cytotoxic effect can be prevented using 
free radical scavengers.
45
Although 3-HK and 3-HAA have been shown 
to be cytotoxic at high concentrations, physiolog-
ical concentrations of 100 nM increased intracel-
lular NAD
+ levels by 18 and 12 per cent respectively, 
with no detectable effect on extracellular LDH 
activity (Figs. 1 and Fig. 2). The contribution of 
3-HK and 3-HAA at these physiological concentra-
tions to neuronal and astroglial cytotoxicity is 
uncertain as micromolar concentrations appear to 
produce neurotoxicity in-vitro.
41,45
The observation that addition of these KP 
metabolites can serve as substrate for NAD
+ synthesis 
at low concentrations (100–500 nM) implies that 
under normal conditions, NAD
+ levels may be 
dependent on substrate availability.
29 We propose 
that astroglial and neuronal KP enzymes downstream 
of QUIN may become saturated in the presence of 
excess extracellular KP metabolites leading to an 
accumulation of QUIN. Indeed, we have previously 
demonstrated that exogenous 3-HAA substantially 
increases QUIN synthesis in human foetal astrocytes 
to neurotoxic levels implying saturation of down-
stream enzymes involved in catabolism of QUIN to 
its essential metabolite, NAD
+.
27 Similarly, Blight 
et al
46 observed that treatment of 4-chloro-3-
hydroxyanthranilate, a synthetic inhibitor of 
3-hydroxyanthranilic acid oxidase, was able to reduce 
QUIN production and functional deﬁ  cits following 
experimental spinal cord injury in guinea pigs.
On the other hand, our results indicate a clear 
dichotomy between exogenous AA effects in human 
neurons and astrocytes. While AA appears neuro-
toxic at concentrations as low as 500 nM, AA 
improved intracellular NAD
+ levels in human 
astrocytes by up to 10% in the 0.5 to 10 μM range 
(Fig. 2). AA has been previously reported to impair 
energy metabolism in the rat cerebral cortex at 
micromolar concentrations, possibly through 
inhibition of complex I–III activities in the mito-
chondrial respiratory chain.
47 While the KP is fully 
expressed in human neurons,
48 kynurenine hydrox-
ylase (KYN-OHase), which converts KYN to 3-HK 
is absent in human foetal astrocytes.
27 Consequently, 
astrocytes cannot produce 3-HK.
27 The KP is divided 
into two parts in human astrocytes (Fig. 1), and KYN 
may be converted to AA by kynureninase which then 
undergoes non-specific hydroxylation to form 
3-HAA and may subsequently be used to form QUIN 
and NAD
+.
27 This suggests a greater requirement for 
AA as a substrate for NAD
+ synthesis in human 
astrocytes compared to human neurons, and AA may 
become cytotoxic to both cell types in excess con-
centrations. These ﬁ  ndings provide insight not only 
in the differences between neurons and astrocytes, 
but also for understanding how different brain cells 
produce NAD
+.
QUIN is an endogenous NMDA receptor agonist 
involved in neuronal ﬁ  ring.
15 The amount of QUIN 
in the brain and CSF is usually less than 100 nM. 
Increased brain QUIN levels (500–1000 nM) have 
been observed in the CSF and serum in several 
inﬂ  ammatory brain diseases, including AD,
49 HD,
45 
traumatic brain injury, AIDS dementia complex 
(ADC),
16 and other infections.
15 QUIN has been 
shown to be up-regulated in ageing and in associa-
tion with senile plaques in the AD brain.
50 The 
results in the study are in line with previously pub-
lished results highlighting the importance of QUIN 
as a beneﬁ  cial substrate for NAD
+ synthesis at low 
concentration, but a putative toxin able to induce 
oligodendrocyte, neuronal, and astroglial apoptosis 
at pathophysiological concentrations.
49,51–53
As previously mentioned, PIC is an endogenous 
metal chelator in the brain, and is an efﬁ  cient chelator 
for minerals such as chromium, zinc, manganese, 
copper, and iron.
23 Unbound (free) redox-active iron 
and copper significantly increase free radical 
generation and are found in abundance in the AD 
brain.
54 Disordered PIC metabolism may yet be found 
to play a role in the pathophysiology of AD. The 
physiological concentration of PIC in human serum 
is thought to be between 100–400 nM.
55 Elevated 
PIC levels have been associated with fatal outcome 
in Malawian children with cerebral malaria.
56 Our 
data shows that PIC can increase intracellular NAD
+ 
levels at physiological concentrations (100 nM). This 
may be partly due to its intracellular metal chelating 
properties reducing the contribution of free redox 
active metals in free radical generation.
57
However, PIC appeared to also induce a dose 
dependent decrease in intracellular NAD
+ and 
increase in extracellular LDH activity in both 
human astrocytes and neurons. These results are 
consistent with one study that observed signﬁ  cant 
PIC induced neurotoxicity that was associated with 
both prolonged exposure time and increased glu-
cose concentration in the culture supernatant.
41 
While the mechanism leading to PIC toxicity is 68
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not known, at high concentrations, PIC may be 
causing disruption to some of the many trace metal 
(Cu
+, Zn
++, Fe
++) dependent biochemical reactions 
essential for normal cell metabolism.
KYNA is a neuroprotective molecule with 
antagonistic properties on both nicotinic-acetylcholine 
and glutamatergic receptors at supra-physiological 
concentrations.
39 The tissue concentrations of KYNA 
in the human brain have been estimated to be 
between 0.2–1.5 μM.
58,59 In our study, no signiﬁ  cant 
changes in intracellular NAD
+ levels and cell 
viability were observed across micromolar concen-
trations in both human primary astrocytes and neu-
rons (Figs. 2 and 3). KYNA exhibits a high afﬁ  nity 
for the glycine-binding site of the NMDA receptor 
at low concentrations, but can act on the glutamate 
binding site on the NMDA receptor, and AMPA 
receptors, at high micromolar concentrations.
39 
Decrease in KYNA levels below the threshold 
needed for NMDA receptor antagonism can enhance 
the vulnerability of dopaminergic neurons to exci-
totoxic insult.
60 Moroni
61 proposed that NMDA and 
glutamate induced excitotoxic neuronal damage can 
be ameliorated by diverting KYN metabolism to 
KYNA synthesis. Likewise, supplementation with 
TRP, an endogenous precursor for KYN synthesis, 
may increase the levels of KYNA and therefore pos-
sibly slow down or prevent the formation of cyto-
toxic concentrations of QUIN.
62,63
This study is the ﬁ  rst to examine the effects of 
extracellular KP metabolites on intracellular NAD
+ 
synthesis and cell death in human primary astro-
cytes and neurons. While a large body of literature 
is available on the toxic effects of KP metabolites 
in regard to neuroinﬂ  ammation, few studies have 
considered the effect of these metabolites on intra-
cellular NAD
+ levels in-vitro. This study demon-
strates that changes in the brain levels of certain KP 
metabolites may be important mediators contribut-
ing to brain cell dysfunction in some neurological 
disorders involving increased KP activation.
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